A relevant study, conducted on a panel of 190 samples derived from patients with breast cancer, showed a significant correlation between AXL and reduced patient survival; in addition, clinical investigations have confirmed a higher expression of AXL in metastatic sites as compared to primary tumors of the same patients, confirming its involvement in tumor progression [81]. The gene discussed is AXL; the disease is neoplasm.